SCHEMBL2907965

SCHEMBL2907965

CC(C)(C)OC(=O)N1CCC(c2ccc(N)c(C3=CCCCC3)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.48
CSF1R P07333 7/20 0.46
CYP2C19 P33261 2/20 0.46
KIT P10721 7/20 0.45
NAMPT P43490 1/20 0.45
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 2/20 0.44
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
BMPR1B O00238 2/20 0.41
PLK4 O00444 2/20 0.41
STK25 O00506 2/20 0.41
RIOK3 O14730 2/20 0.41
CHEK1 O14757 2/20 0.41
GAK O14976 2/20 0.41
DCLK1 O15075 2/20 0.41
MUSK O15146 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3165154 0.99 PDE4B (0.47) PDE4BCSF1RCYP2C19KITNAMPT
SCHEMBL25211356 0.97 PDE4B (0.46) PDE4BCSF1RCYP2C19KITNAMPT
SCHEMBL2907750 0.97 PDE4B (0.48) PDE4BCSF1RCYP2C19KITNAMPT
SCHEMBL25538690 0.96 PDE4B (0.47) PDE4BCSF1RCYP2C19KITNAMPT
SCHEMBL25204517 0.95 PDE4B (0.54) PDE4BCSF1RCYP2C19KITNAMPT
SCHEMBL2916006 0.85 CSF1R (0.56) CSF1RCYP2C19KITHDAC1HDAC2
SCHEMBL2908137 0.85 NAMPT (0.44) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL2938527 0.84 DDB1 (0.44) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL3168637 0.84 DDB1 (0.44) PDE4BNAMPTKDM4EMAPTTHRB
SCHEMBL13096657 0.83 HDAC1 (0.36) PDE4BCSF1RCYP2C19KITHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118743770-A Positron Emission Tomography (PET) radiotracer for imaging macrophage colony stimulating factor 1 receptor (CSF 1R) in neuroinflammation 约翰霍普金斯大学 2024-10-08 CN disclosed
US-20240308994-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) 2024-09-19 US disclosed
WO-2023096304-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF 한양대학교 에리카산학협력단 2023-06-01 WO disclosed
WO-2023096304-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF 한양대학교 에리카산학협력단 2023-06-01 WO disclosed
US-20210290784-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION THE JOHNS HOPKINS UNIVERSITY 2021-09-23 US disclosed
US-20210290784-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION THE JOHNS HOPKINS UNIVERSITY 2021-09-23 US disclosed
EP-3813890-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION The Johns Hopkins University (US) 2021-05-05 EP disclosed
CN-112638431-A Positron Emission Tomography (PET) radiotracers for imaging macrophage colony stimulating factor 1 receptor (CSF1R) in neuroinflammation 约翰霍普金斯大学 2021-04-09 CN disclosed
US-9526731-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2016-12-27 US disclosed
US-9526731-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2016-12-27 US disclosed
WO-2007124369-A2 METHOD OF INHIBITING C KIT KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
EP-1807077-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-28 US disclosed
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-28 US disclosed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 WO disclosed
WO-2006138155-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-28 WO disclosed
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 US disclosed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 US disclosed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189623-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES PDE4B 4132/4885CSF1R 34/4885CYP2C19 3150/4885
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR FLT3, MCL1, CSF1R PDE4B 3299/4885CSF1R 3/4885CYP2C19 2318/4885
US-20060148812-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES PDE4B 4132/4885CSF1R 34/4885CYP2C19 3150/4885
US-20210290784-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION CSF1R, CSF3R, CMKLR1 PDE4B 2938/4885CSF1R 1/4885CYP2C19 4002/4885
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE FLT3, PLK1, PHKG1 PDE4B 4270/4885CSF1R 149/4885CYP2C19 4377/4885
US-20240308994-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF CSF1R, CSF3R, IL15RA PDE4B 324/4885CSF1R 1/4885CYP2C19 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.